Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03043391 · OUTCOME

Percentage of Participants With Unacceptable Toxicity

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children · Source last updated 2024-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
14 days after treatment with PVSRIPO

What was measured

Percentage of participants with unacceptable toxicity during the 14-day period post-PVSRIPO treatment

Groups in this outcome

All Participants Treated

All participants received a single open-label infusion of lerapolturev

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Participants Treated8

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Participants Treated0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Percentage of participants with unacceptable toxicity during the 14-day period post-PVSRIPO treatment
groups
  1. description
    All participants received a single open-label infusion of lerapolturev
    id
    OG000
    title
    All Participants Treated
param Type
NUMBER
reporting Status
POSTED
time Frame
14 days after treatment with PVSRIPO
title
Percentage of Participants With Unacceptable Toxicity
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice